Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) has emerged as a popular minimally invasive alternative to open resective surgery for drug-resistant epilepsy (DRE). We sought to perform a systematic review… Click to show full abstract
Magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) has emerged as a popular minimally invasive alternative to open resective surgery for drug-resistant epilepsy (DRE). We sought to perform a systematic review and individual participant data meta-analysis (IPDMA) to identify independent predictors of seizure outcome and complications following MRgLITT for DRE. Eleven databases were searched from January 1st , 2010 to February 6th , 2021 using the terms: "MR-guided Ablation Therapy" and "epilepsy". Multivariable mixed-effects Cox and logistic regression identified predictors of time-to-seizure recurrence, seizure freedom, operative complications, and postoperative neurological deficits. From 8,705 citations, 46 studies reporting on 450 MRgLITT DRE patients (mean age 29.5±18.1 years, 49.6% female) were included. Median postoperative seizure freedom and follow-up duration were 15.5 and 19.0 months, respectively. Overall, 240 (57.8%) of 415 patients (excluding palliative corpus callosotomy) were seizure free at last follow-up. Generalized seizure semiology (HR=1.78, p=0.020) and non-lesional MRI findings (HR=1.50, p=0.032) independently predicted faster time-to-seizure recurrence. Cerebral cavernous malformation (CCM) (OR=7.97, p<0.001) and mesial temporal sclerosis/atrophy (MTS/A) (OR=2.21, p=0.011) were independently associated with greater odds of seizure freedom at last follow-up. Operative complications occurred in 28 (8.5%) of 330 patients and were independently associated with extratemporal ablations (OR=5.40, p=0.012) and non-lesional MRI studies (OR=3.25, p=0.017). Postoperative neurological deficits were observed in 53 (15.1%) of 352 patients and were independently predicted by hypothalamic hamartoma (HH) (OR=5.92, p=0.006) etiology and invasive EEG monitoring (OR=4.83, p=0.003). Overall, MRgLITT is particularly effective in treating patients with well-circumscribed lesional DRE, such as CCM and MTS/A, but less effective in non-lesional cases or lesional cases with a more diffuse epileptogenic network associated with generalized seizures. This study identifies independent predictors of seizure freedom and complications following MRgLITT that may help further guide patient selection for MRgLITT.
               
Click one of the above tabs to view related content.